Acute Viral Hepatitis (HAV, HBV, HCV)
Use
Aid in the diagnosis of acute viral hepatitis due to infection with HAV, HBV, and/or HCV.
Special Instructions
If reflex testing is performed, additional charges/CPT code(s) may apply. Patients consuming high doses of biotin should stop intake at least 72 hours prior to sample collection due to interference risk.
Limitations
The assays in this panel have not been FDA cleared or approved for the screening of blood or plasma donors. Assay performance characteristics have not been established for immunocompromised or immunosuppressed patients, cord blood or patients less than 2 years of age. Use in cadaveric specimens remains undetermined.
Methodology
Immunoassay (ECLIA)
Biomarkers
LOINC Codes
- 24363-4
- 13950-1
- 5196-1
- 24113-3
- 13955-0
Result Turnaround Time
1-2 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
5 mL
Minimum Volume
2.5 mL
Container
Gel-barrier tube or serum transfer tube
Collection Instructions
Centrifuge sample within 24 hours of collection. If tube other than a gel-barrier tube is used, or if sample will be shipped frozen, transfer separated serum to a screw-cap polypropylene transport tube.
Patient Preparation
Patients should be cautioned to stop biotin consumption at least 72 hours prior to the collection of a sample.
Storage Instructions
Refrigerated (preferred). HAV and HBV: stable 14 days at room temperature, refrigerated (preferred) and frozen. HCV: stable 24 hours at room temperature, 6 days refrigerated or 6 weeks frozen.
Causes for Rejection
Heat-inactivated specimens; cord blood; cadaveric specimens; or body fluids other than serum or EDTA plasma; gross hemolysis; excessive lipemia; improper labeling; frozen gel-barrier tube.
